Please assess the completion status of the following clinical trial:

Trial Title: Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed locally advanced or metastatic colorectal cancer~* Measurable or evaluable disease according to the Response Evaluation Criteria in Solid Tumors~* ECOG performance status ≤ 2~* Age 18 - 72 years~* Patients who progress after 1st line therapy with FOLFOX/AVASTIN~* Adequate liver (Bilirubin ≤ 1.5 upper normal limit, SGOT/SGPT ≤ 4 upper normal limit, ALP ≤ 2.5 upper normal limit) renal (Creatinine ≤ 1.5 upper normal limit) and bone marrow (ANC ≥ 1,500/mm3, PLT ≥100,000/mm3) function~* Patients must be able to understand the nature of this study~* Written informed consent~Exclusion Criteria:~* History of serious cardiac disease (unstable angina, congestive heart failure,uncontrolled cardiac arrhythmias)~* History of myocardial infarction or stroke within 6 months~* Clinically significant peripheral vascular disease~* History of abdominal fistula, gastrointestinal perforation or intraabdominal abscess within 28 days prior to Day 0~* Major surgical procedure, open biopsy, or significant traumatic injury within 30 days prior to Day 1~* Presence of central nervous system or brain metastasis~* Evidence of bleeding diathesis or coagulopathy~* Blood pressure \> 150/100 mmHg~* Pregnant or lactating woman~* Life expectancy \< 3 months~* Previous radiotherapy within the last 4 weeks or \> 25% of bone marrow~* Metastatic infiltration of the liver \> 50%~* Patients with chronic diarrhea (at least for 3 months) or partial bowel obstruction or total colectomy~* Active infection requiring antibiotics on Day 1~* Second primary malignancy, except for non-melanoma skin cancer and in situ cervical cancer~* Psychiatric illness or social situation that would preclude study compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 72 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): XELIRI/Avastin

Based on this trial design, predict the completion outcome and termination type (if applicable).